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Background. .e Parkinson’s Disease Composite Scale (PDCS) is a recently developed easy-to-use tool enabling a timely but
comprehensive assessment of Parkinson’s disease (PD)-related symptoms. Although the PDCS has been extensively validated, its
responsiveness to acute levodopa challenge has not been demonstrated yet. Objective. To investigate the correlation between
changes in the motor examination part of the Movement Disorder Society-sponsored Uniﬁed Parkinson’s Disease Rating Scale
(MDS-UPDRS) and the PDCS motor scores during acute levodopa challenge and calculate a cutoﬀ range on the PDCS indicating
clinically relevant improvement.Methods. A consecutive series of 100 patients with parkinsonism were assessed using the motor
examination sections of the MDS-UPDRS and the PDCS at least 12 hours after the last levodopa dose and after the administration
of a single dose of a suprathreshold immediate formulation of levodopa/benserazide reaching the “best ON.” Results. .ere was a
high correlation between changes in the MDS-UPDRS and the PDCS motor scores (Spearman’s rho� 0.73, p< 0.001). Receiver
operating characteristic analysis revealed that a 14.6%–18.5% improvement in the PDCS motor scores corresponds to a 20–30%
improvement in the MDS-UPDRS motor examination. Conclusions. .e PDCS can reliably and adequately respond to an acute
levodopa challenge. Any improvements in PDCS motor scores exceeding the 14.6–18.5% threshold could represent a clinically
relevant response to levodopa.
1. Introduction
Parkinson’s disease (PD) is associated with numerous and
quite heterogeneous symptoms. .erefore, there is a high
need from both clinical and research perspectives to com-
prehensively assess these problems. Although various tools,
including the Movement Disorder Society-sponsored Uni-
ﬁed Parkinson’s Disease Rating Scale (MDS-UPDRS) [1], the
Hoehn and Yahr Scale (HYS) [2], the Clinical Impression of
Severity Index for Parkinson’s Disease (CISI) [3], the Non-
Motor Symptoms Scale (NMSS) [4], the Uniﬁed Dyskinesia
Rating Scale [5], and the Montreal Cognitive Assessment
(MoCA) [6], are available, these instruments still have some
weaknesses. While the MDS-UPDRS measures the PD-re-
lated symptoms in a holistic approach, assessment of this
scale is time-consuming. On the other hand, the use of the
other aforementioned scales is somewhat faster and simpler;
however, they focus on certain problems and consequently
cannot provide a comprehensive picture. Moreover, the
majority of the available assessment tools (e.g., MDS-
UPDRS and MoCA) are copyrighted, which may limit their
applicability. Because there was no single validated, reliable,
highly responsive, and timely assessable tool, which can
holistically measure the main motor and nonmotor symp-
toms of PD and suitable for both everyday clinical practice
and research purposes, the European Parkinson’s Disease
Association sponsored the development of the Parkinson’s
Disease Composite Scale (PDCS).
Introduced in 2016 [7], the PDCS is a rater-based simple
and relatively quick instrument measuring various aspects of
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PD including the severity of motor (6 items) and nonmotor
symptoms (6 items), treatment-related complications (4
items), and PD-related disability (1 item). Motor symptoms
are evaluated by the healthcare professional at the time of the
visit, while nonmotor symptoms, treatment-related com-
plications, and PD-related disability are rated based on the
experience of the patient over the two weeks prior to the
examination. Although each item can be rated as absent,
mild, moderate, severe, or very severe, the scoring is
asymmetric. Some clinically relevant problems (e.g., cog-
nitive problems, postural instability, and falls) are scored
from 0 to 7, while other less disabling problems have a range
of 0–4. .is unique scoring system enables the weighted
measure of clinically disabling symptoms. Besides calcu-
lating the diﬀerent domains, a total score can also be
formulated.
.e ﬁrst validation study on the PDCS has found that
this new scale seems to be feasible, acceptable, reproducible,
valid, and precise [8]..ese results have been reinforced by a
further more extensive validation study which involved over
750 patients from 20 centers of 11 countries [9].
As the PDCS is a recently developed instrument, some
of its potential scopes have not yet been studied. To the
best knowledge of the authors, the PDCS has not been
used in interventional studies, and consequently, there are
no data available demonstrating its capability to
detect clinical change. .erefore, we aimed to investigate
the responsiveness of the PDCS to an acute levodopa
challenge.
2. Materials and Methods
.e study protocol was similar to the procedure utilized by
Merello et al. to analyze the performance of the MDS-
UPDRS motor section assessing the response to an acute
levodopa challenge [10]. A consecutive series of patients with
parkinsonism, undergoing an acute levodopa challenge at
the Department of Neurology, University of Pe´cs, Hungary,
between 2017 and 2018 were enrolled in this prospective
study. .e study protocol was approved by the Regional and
Institutional Ethical Committee (3617.316-24987/KK41). In
de novo or early-phase patients, the acute dopaminergic
challenge was used for helping the diﬀerential diagnosis of
parkinsonian syndromes, while in advanced PD cases it is
used for evaluating the feasibility of patients for deep brain
stimulation. If an adverse event interfering with the outcome
(e.g., nausea, vomiting, and hypotension) occurred during
the test, the patient was excluded. To minimize these events,
patients were pretreated with domperidone (30mg/day)
12–72 hours before and on-demand again 1 hour before the
administration of levodopa.
In the case of those patients who were on anti-
parkinsonian medication, any form of levodopa was dis-
continued at least 12 hours prior (usually an overnight
withdrawal) to achieve an OFF state. Long-acting dopamine
agonists (e.g., pramipexole, ropinirole, and rotigotine) and
monoamine oxidase-B inhibitors (e.g., rasagiline and sele-
giline) were withdrawn at least for 48 hours.
All examinations were performed by two highly expe-
rienced nurse practitioners. First, we assessed the motor
sections of the MDS-UPDRS and the PDCS in the morning
between 8 and 9 a.m. corresponding to an OFF state.
Subsequently, we rated these instruments in ON state usually
60–90minutes after the administration of 200–400mg im-
mediate-release formulation of levodopa/benserazide pills
(Madopar® Dispersible, Roche). .ose patients, who hadchronically been treated previously with antiparkinsonian
medications, were asked to decide whether the achieved ON
state corresponds to their best ON. If not, further 50–100mg
levodopa was administered and this dose was repeated until
the best ON state was achieved.
In addition to the MDS-UPDRS Part III and the PDCS,
further neurological and neuropsychological examinations
were performed for the better characterization of the study
population. .e severity of PD-related symptoms was
globally assessed by the Hungarian validated versions of the
other parts of the MDS-UPDRS [11], the HYS, and the
CISI-PD. To assess nonmotor symptoms globally, the
validated Hungarian version of the NMSS [12] was also
included. Besides, neurocognitive performance, apathy,
anxiety, and depression were also assessed by the MoCA
[13, 14], the Lille Apathy Rating Scale [15], the Parkinson
Anxiety Scale [16], the Montgomery–Asberg Depression
Rating Scale [17], and the Parkinson’s Disease Sleep Scale
2nd version [18, 19]. .e 39-item Parkinson’s Disease
Questionnaire [20] was used to measure the disease-spe-
ciﬁc health-related quality of life.
.e IBM SPSS software package (version 24.0.2, IBM
Inc., Armonk, NY, USA) was used for statistical calculations.
To test normality, Shapiro–Wilk test was utilized. Because
some data from the applied scales did not follow the normal
distribution, median and 25–75 percentiles were also shown
besides the mean± standard deviation values.
For correlation, Spearman’s rank correlation coeﬃcients
were calculated by analyzing the association between MDS-
UPDRS and PDCS motor changes due to the acute levodopa
challenge. For correlation coeﬃcients, the values 0–0.29
were indicative of weak correlation, the values 0.30–0.59
were indicative of moderate association, and the values
0.60–1.00 were considered as high association [21].
.ere is no exact deﬁnition for the clinically relevant
response to acute levodopa challenge available. A consensus
report suggested that at least 20–30% improvement in
UPDRS III is required depending on the aim of the testing
[22]. In a more recent single-center study, Merello et al.
suggested that a 24.5% improvement in the MDS-UPDRS
Part III seems to be clinically relevant [10]. .erefore, we
considered the acute levodopa challenge positive if at least
24.5% improvement was documented on the MDS-UPDRS
Part III.
Subsequently, receiver operating characteristic (ROC)
analysis was performed. Improvements in the PDCS motor
score corresponding to 20%, 24.5%, and 30% improvements
in the MDS-UPDRS Part III were identiﬁed. To calculate the
best cutoﬀ values with the most optimal sensitivity and
speciﬁcity, the Youden method was used [23]. .e statistical
signiﬁcance level was set at 0.01.
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3. Results
A total of 100 consecutive patients (47 females), aged
66.0± 9.7 years, were enrolled. Of them, 20 patients had de
novo or early phase of parkinsonism. .e mean duration of
disease was 4.7± 4.5 years. Almost half of the patients (49%)
suﬀered from mild (HYS 1&2) parkinsonism, while 23
patients had moderate (HYS 3) and 28 patients had severe
(HYS 4&5) stage. Baseline characteristics of the study
population (e.g., demographic and disease-speciﬁc data) are
presented in Table 1.
Levodopa test was positive in 83 cases, while negative
results indicated other parkinsonian syndromes responsible
for the symptoms in 17 patients (Table 2). Mean MDS-
UPDRS and PDCS motor scores were 45.1± 15.3 and
13.7± 6.2 points in OFF and 33.2± 15.2 and 10.1± 6.5 points
in ON state, respectively. According to these data, an average
of 27.0± 20.1% (− 11.9 points) and 28.7± 30.3% (− 3.6 points)
reduction of MDS-UPDRS and PDCS motor scores could be
achieved by administering levodopa (Table 2). Changes in
the motor scores of the MDS-UPDRS and the PDCS oc-
curring during an acute levodopa challenge by disease type
are shown in Table 3.
High level of correlation (Spearman’s rho� 0.726,
p< 0.001) was found between changes in MDS-UPDRS and
PDCSmotor scores (Figure 1)..e level of correlation varied
according to the disease type from 0.465 (non-PD group) to
0.806 (tremor-dominant PD, Table 3).
.e area under the ROC curve (AUC) for the change in
PDCS motor score corresponding to the clinically relevant
20% improvement in the MDS-UPDRS Part III was 0.883
(p< 0.001; Figure 2). .e area under the ROC curve for the
improvement in PDCS motor score corresponding to the
24.5% change in the motor examination part of the MDS-
UPDRS was 0.885 (p< 0.001; Figure 3), while the area
under the ROC curve for the change in PDCS motor score
corresponding to the 30% improvement in the MDS-
UPDRS motor score was 0.883 (p< 0.001; Figure 4). .e
cutoﬀ values for improvements in the PDCS motor scores,
which indicate a clinically relevant response to acute
levodopa challenge with the most optimal sensitivity and
speciﬁcity and correspond to the 20%, 24.5%, and 30%
changes in the MDS-UPDRS Part III, were 14.6%, 16.6%,
and 18.5% (Table 4).
4. Discussion
To demonstrate the responsiveness of the motor domain of
the PDCS to clinical change, we measured the improvement
in both the MDS-UPDRS and the PDCS during acute
levodopa challenge. Ideally, a clinical scale, such as the
PDCS, should adequately detect the improvement in motor
symptoms and diﬀerentiate the responders from the
nonresponders.
We calculated the correlation between the changes in
motor scores of the PDCS and the MDS-UPDRS, and we
determined subsequently the minimum required improve-
ment in the motor score of the PDCS corresponding to a
clinically relevant improvement.
Internationally accepted diagnostic criteria of United
Kingdom Parkinson’s Disease Society Brain Bank for idi-
opathic Parkinson’s disease include the responsiveness of
motor signs of the disease to levodopa [24]. .erefore, an
acute levodopa challenge, which is the standard way of
testing this supportive prospective criterion, can help con-
ﬁrm or refute the clinical diagnosis of the disease.
Motor examination parts of the UPDRS and the MDS-
UPDRS are the standard tools for measuring the im-
provement of motor symptoms developing due to the ad-
ministration of a single dose of levodopa. At present, only a
consensus-based deﬁnition of the clinically relevant re-
sponse to acute levodopa challenge is available for clinical
practice. According to this deﬁnition, if acute levodopa
improves the motor score of a drug-naı¨ve PD patient by at
least 20% compared to baseline, the acute challenge can be
considered as positive. However, a positive acute response to
levodopa should be deﬁned based on the aim of testing in
treated patients [22]. A minimum threshold of 30% im-
provement in motor score compared to baseline was ac-
cepted as a clinically relevant change, indicating a positive
chronic response to levodopa [22]. .is empirically adopted
30% improvement has been conﬁrmed to be a sensitive and
speciﬁc threshold value predicating sustained long-term
levodopa response by Merello et al. [25]. To conclude,
current recommendations consider the 20% or 30% im-
provements in the UPDRS Part III to be clinically relevant.
However, such threshold values are not available for the
MDS-UPDRS. Although Merello et al. described that an
approximately 24.5% improvement in the MDS-UPDRS
Part III corresponds to an approximately 30% improvement
in the UPDRS Part III [10], this ﬁnding has not yet been
conﬁrmed by other groups which make its generalizability
uncertain. A major weakness of the previously established
cutoﬀ values may be that they can be highly sample de-
pendent which considerably interferes with their applica-
bility in clinical research. We, therefore, calculated the
discriminating threshold values of PDCS motor score for
both the 20%, 24.5%, and 30% improvements in the MDS-
UPDRS Part III and, as a result, established a range between
14.6% and 18.5% improvements in the PDCS motor score
which may be more applicable, compared to an exact
threshold value, even for study populations diﬀering from
the present sample.
Fulﬁlling our expectations, we found a good and sig-
niﬁcant correlation between MDS-UPDRS Part III changes
and PDCS motor score changes. We also demonstrated that
PDCS can diﬀerentiate responders and nonresponders to
levodopa. .e cutoﬀ values of 20%, 24.5%, and 30% in the
motor examination part of the MDS-UPDRS for sustained
levodopa response were equivalent to 14.6%, 16.6%, and
18.5% improvements in the PDCS motor score.
Merello et al. have demonstrated an excellent correlation
between the motor examination parts of the UPDRS and the
MDS-UPDRS both before (Pearson’s R� 0.965) and after
(Pearson’s R� 0.968) acute levodopa challenge [10]. .e
correlation coeﬃcient between the MDS-UPDRS Part III
and the PDCS motor scores, which was found by a recent
validation study using data of 776 patients (the ﬁndings of
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this study are awaiting for publication), was high (Spear-
man’s R� 0.81) but not as strong as the correlation co-
eﬃcient between the UPDRS and its successor version
(MDS-UPDRS) found byMerello et al.We also found a good
but not an excellent correlation between the changes in
motor scores of the MDS-UPDRS and the PDCS during
acute levodopa challenge. A possible reason for the lower
correlation coeﬃcient between these two scales (MDS-
Table 1: Baseline characteristics of the study population.
Mean or
count
Standard deviation or
percentage Median
25th
percentile
75th
percentile
Age (years) 66.0 9.7 66 60 74
Disease duration (years) 4.7 4.5 4 1 7
Levodopa duration (years) 4.7 4.3 4 1 7
Sex Males 53 53.0%Females 47 47.0%
Handedness Right 96 96.0%Left 4 4.0%
Dominant side Right 33 37.5%Left 55 62.5%
BMI (kg/m2) 26.3 5.4 26.4 23.3 29.4
Education (years) 12.4 3.2 12 11 15
Disease type
Tremor-dominant PD 24 24.0%
Rigid-akinetic PD 35 35.0%
Mixed PD 24 24.0%
Non-PD (other parkinsonian
syndromes) 17 17.0%
De novo No 75 75.0%Yes 25 25.0%
Hoehn and Yahr
stage
Mild (1 and 2) 49 49.0%
Moderate (3) 23 23.0%
Severe (4 and 5) 28 28.0%
MDS-UPDRS I. nM-EDL 14.2 7.4 15 7 19
MDS-UPDRS II. M-EDL 17.5 8.9 16 10 24
MDS-UPDRS III. ME 35.3 16.0 37 22 47
MDS-UPDRS IV. MC 5.0 4.0 4 2 7
MDS-UPDRS total score 71.9 28.9 72 48 93
PDCS motor score 13.4 6.3 13 10 18
PDCS nonmotor score 9.3 6.1 10 3 14
PDCS treatment-related complications score 5.5 3.9 4 2 9
PDCS disability score 2.4 1.9 2 1 4
PDCS total score 28.2 13.3 26 18 37
CISI total score 8.7 3.5 9 6 11
PDQ-39 summary index 29.1 16.5 30 16 41
MADRS total score 13.8 7.6 14 19 8
PAS total score 14.1 7.2 14 19 9
LARS total score − 21.1 10.9 − 24 − 16 − 28
MoCA total score 22.4 5.5 24 27 18
PDSS-2 total score 19.9 11.8 19 28 10
NMSS I. Cardiovascular problems 3.9 4.3 2 8 0
NMSS II. Sleep problems 12.2 9.2 12 20 4
NMSS III. Mood problems 12.0 14.0 6 21 2
NMSS IV. Hallucinations 1.0 2.8 0 0 0
NMSS V. Memory problems 4.3 5.3 2 7 0
NMSS VI. Gastrointestinal problems 4.7 6.0 2 8 0
NMSS VII. Urinary problems 11.0 10.8 8 20 2
NMSS VIII. Sexual problems 0.8 2.3 0 0 0
NMSS IX. Miscellaneous 4.2 6.4 2 7 0
NMSS total score 54.1 39.6 49 82 20
BMI� body mass index; CISI�Clinical Impression of Severity Index; LARS� Lille Apathy Rating Scale; MADRS�Montgomery–Asberg Depression Rating
Scale; MDS-UPDRS�Movement Disorder Society-sponsored Uniﬁed Parkinson’s Disease Rating Scale; MDS-UPDRS I. nM-EDL� nonmotor experiences of
daily living (Part I of MDS-UPDRS); MDS-UPDRS II. M-EDL�motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS III. ME�motor
examination (Part III of MDS-UPDRS); MDS-UPDRS IV. MC�motor complication (Part IV of MDS-UPDRS); MoCA�Montreal Cognitive Assessment;
NMSS�Non-Motor Symptoms Scale; PAS�Parkinson Anxiety Scale; PD� Parkinson’s disease; PDCS�Parkinson’s Disease Composite Scale; PDSS-
2�Parkinson’s Disease Sleep Scale 2nd version; PDQ-39� 39-item Parkinson’s Disease Questionnaire.
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UPDRS and PDCS) may be the shorter number of items of
the PDCS and the heterogeneous scoring of the PDCSmotor
items, which results from the weighting of the items based
on clinical relevance of a particular symptom, in comparison
with the motor parts of the UPDRS and the MDS-UPDRS
having more items to correlate which are scored uniformly.
.e strength of our study partly lies in the study pop-
ulation which also included patients with non-PD parkin-
sonism. Another strength of the present study may be that
we used a range of improvement in the MDS-UPDRS motor
scores indicating a clinically relevant response to levodopa
for the identiﬁcation of a range of variation in the PDCS
motor scores demonstrating good levodopa response. .e
Table 2: Average changes in MDS-UPDRS and PDCS motor scores during acute levodopa challenge.
OFF state∗ (points) ON state∗∗ (points) Change (points) Change (%)
MDS-UPDRS Part III 45.1± 15.3 33.2± 15.2 − 11.9± 10.1 − 27.0± 20.1
PDCS motor score 13.7± 6.2 10.1± 6.5 − 3.6± 4.0 − 28.7± 30.3∗Any antiparkinsonian medication was discontinued at least 12 hours before the assessment. ∗∗60minutes after a single dose of 200–400mg immediate-
release formulation of levodopa/benserazide or in the best ON state. Data are mean± standard deviation. MDS-UPDRS�Movement Disorder Society-
sponsored Uniﬁed Parkinson’s Disease Rating Scale; PDCS�Parkinson’s Disease Composite Scale.
Table 3: Average ON andOFF values and their changes inMDS-UPDRS and PDCSmotor scores by disease type during levodopa challenge.
Disease type
Tremor-dominant
PD
Rigid-akinetic
PD Mixed PD
Non-PD (other parkinsonian
syndromes)
MDS-UPDRS OFF (points) 45.3± 15.3 43.3± 16.5 48.3± 15.4 44.3± 13.1
MDS-UPDRS ON (points) 31.3± 13.5 29.6± 17.00 35.3± 13.9 40.5± 13.5
MDS-UPDRS change (points) − 14.0± 10.6 − 13.7± 10.3 − 13.1± 10.5 − 3.8± 2.4
MDS-UPDRS change (%) − 29.7± 20.6 − 33.5± 21.6 − 26.9± 16.7 − 9.9± 8.3
PDCS OFF (points) 12.0± 5.8 14.0± 6.8 14.2± 5.7 14.8± 6.0
PDCS ON (points) 8.0± 5.4 8.8± 7.0 11.3± 5.8 14.1± 6.0
PDCS change (points) − 4.0± 3.8 − 5.2± 4.7 − 2.9± 3.2 − 0.7± 1.0
PDCS change (%) − 33.0± 28.0 − 42.0± 34.7 − 21.6± 24.5 − 5.6± 8.2
Correlation (Spearman’s rho) between
changes in MDS-UPDRS (%) and PDCS (%) 0.806 (p< 0.001) 0.776(p< 0.001) 0.685(p< 0.001) 0.465 (p< 0.001)
Data are mean± standard deviation. Assessments in OFF state were performed at least 12 hours after the discontinuation of any antiparkinsonianmedication.
Patients were reassessed 60minutes after a single dose of 200–400mg immediate-release formulation of levodopa/benserazide or in the best ON state. MDS-
UPDRS�Movement Disorder Society-sponsored Uniﬁed Parkinson’s Disease Rating Scale; PD�Parkinson’s disease; PDCS�Parkinson’s Disease Com-
posite Scale.
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Figure 1: Correlation between the changes in motor scores of the
MDS-UPDRS and the PDCS. Changes in the motor scores are
presented in percentage.
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Figure 2: Receiver operating characteristic curve for illustrating
the discriminating ability of the change in the PDCS motor score
corresponding to a 20% change in theMDS-UPDRS Part III (motor
examination).
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Figure 3: Receiver operating characteristic curve for illustrating the discriminating ability of the change in the PDCS motor score
corresponding to a 24.5% change in the MDS-UPDRS Part III (motor examination).
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Figure 4: Receiver operating characteristic curve for illustrating the discriminating ability of the change in the PDCS motor score
corresponding to a 30% change in the MDS-UPDRS Part III (motor examination).
Table 4: Corresponding changes in the motor scores of the Parkinson’s Disease Composite Scale to the clinically relevant 20%, 24.5%, and
30% changes in the motor examination part of the MDS-UPDRS∗.
PDCS improvement (%) Sensitivity Speciﬁcity Youden’s index +LR − LR AUC ROC p value
MDS-UPDRS 30% improvement 18.47 0.811 0.894 0.705 7.626 0.211 0.883 <0.001
MDS-UPDRS 24.5%
improvement 16.59 0.857 0.863 0.720 6.245 0.166 0.885 <0.001
MDS-UPDRS 20% improvement 14.64 0.830 0.872 0.703 6.503 0.195 0.883 <0.001
.e cutoﬀ values were proposed as benchmarks based on [10, 22]. AUC� area under the curve; +LR� positive likelihood ratio; − LR�negative likelihood
ratio; MDS-UPDRS�Movement Disorder Society-sponsored Uniﬁed Parkinson’s Disease Rating Scale; PDCS�Parkinson’s Disease Composite Scale;
ROC� receiver operating characteristic.
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use of a range instead of an exact threshold value may
provide the wider and more convenient applicability of our
results because they are less dependent on the characteristics
of the investigated patient population and they, therefore,
should not be newly calculated for each study in which they
are planned to be used.
To conclude, the PDCS seems to be adequately re-
sponsive to the acute levodopa challenge based on the good
correlation between changes in the MDS-UPDRS and PDCS
motor scores during the test. Any improvement in the PDCS
motor score equal to or greater than 14.6% seems to
demonstrate levodopa responsiveness. .ese results may be
helpful for centers which plan to integrate the use of PDCS
motor section into their protocols for performing acute
levodopa challenge.
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